Paris Half Marathon 2026
Be a part of our 50th anniversary team at the iconic Paris Half Marathon 2026! Join #TeamRetinaUK and soak up the incredible atmosphere as you run through the French capital.
Search
Search results
Hope for the future
In this article, we hear Colin's story and the reasons why he has hope for the future.
London Landmarks Half Marathon 2026
Soak up the iconic London Landmarks Half Marathon 2026 and join #TeamRetinaUK for an incredible atmosphere as you run through the capital.
Shakespeare Marathon 2026
Run with #TeamRetinaUK at the Shakespeare Marathon 2026, during our special year of 50th anniversary events.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Cell-ebrating the dosing of patients with jCell in a phase 2 clinical trial for RP
The latest research news from Retina UK.
Slowing sight loss in stargardts: Ocugen’s gene therapy trial offers promising early results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Ocugen completes dosing of GARDian3 trial for OCU410ST ahead of schedule
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
Genetic counselling
Genetic counsellors are specially trained healthcare professionals with extensive scientific knowledge who spend time talking to families living with inherited conditions.